Double-Blind Naltrexone in Kleptomania

NCT00332579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-07-29

Study results available
· View outcomes & findings →

Summary

The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.

Conditions

  • Kleptomania

Interventions

DRUG

Naltrexone

daily

DRUG

Placebo

daily

Sponsors & Collaborators

Principal Investigators

  • Jon E Grant, MD, JD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-01
Primary Completion
2008-09-01
Completion
2008-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332579 on ClinicalTrials.gov